Refine your search

Search Results within category "Blood Disorders"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Blood Disorders"


12 Study Matches

Site for ATHN 10: Leveraging the ATHNdataset to Document the State of Rare Coagulation Disorders in the United States

This is a multi-center project in which the American Thrombosis & Hemostasis Network (ATHN) will offer free genotyping to individuals with Rare Coagulation Disorders (RCD).
Lisa Baker at lbaker@pennstatehealth.psu.edu or 717-531-7468
All
All
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Subject must have an established Rare Coagulation Disorder diagnosis (
Must currently receive or have received care at and ATHN affiliated HTC
Subject must have opted into the ATHNdataset
Exclusion Criteria:
Subject is unwilling to sign informed consent form
Blood Disorders
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Gene-transfer, open-label, dose-escalation study of SPK-8011 [recombinant adeno-associated viral vector with B-domain deleted human factor VIII gene] in individuals with hemophilia A

Gene-transfer, open-label, dose-escalation study of SPK-8011 in individuals with hemophilia A. Primary Objective to evaluate the safety, tolerability and efficacy of SPK-8011 a recombinant adeno-associated viral vector with B-domain deleted human factor VIII gene.
Cynthia Campbell-Baird at cbaird@pennstatehealth.psu.edu or 717-531-5777
Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03003533
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Hemophilia A
FVIII Level <1% or 1-2% with> 10 bleeds past 52 weeks or 1-2% on prophy treatment
Greater than 150 exposure days to Factor VIII concentrate or cryo
No evidence of Factor VIII Inhibitor
Acceptable lab values as defined by protocol
Exclusion Criteria:
Active Hep B or C &/or current antiviral therapy for Hep B or C
Significant underlying liver disease, cancer, GI disease, latent infectious disease
HIV-1 or HIV-2 with CD4 count </=l to 200
Other investigational product in the past 12 weeks or gene therapy research within the past 52 weeks
Any other significant condition/disease that in the opinion of the investigator would make the subject unsuuitable
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

Study of the safety of unlicensed cord blood units for stem cell transplant of children and adults.
Suzanne Treadway at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT01656603
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
You have a disorder affecting your hematopoietic system (the organs and tissues that produce your blood) that is inherited, acquired, or from previous chemotherapy
Exclusion Criteria:
You are receiving licensed cord blood products
You are receiving unlicensed CB products from other CB banks
Blood Disorders, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) &lt; 6 years with severe hemophilia A (FVIII &lt; 1%)

Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) &lt; 6 years with severe hemophilia A (FVIII &lt; 1%)
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT02615691
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
< 6 years old at the time of screening
previously untreated with < 3 EDs to ADVATE, BAX 855 or FFP any time prior to screening
severe hemophilia A (FVIII < 1%)
Exclusion Criteria:
History or current FVIII inhibitory antibodies (≥ 0.6 BU
Diagnosis of an inherited or acquired hemostatic defect other than hemophilia A
Previously treated with cryo, PRBC, platelets or any type of FVIII concentrate other than ADVATE, BAX 855v or FFP
weight is < 5 kg
Platelet count < 100,000/mL; severe chronic hepatic dysfunction or severe renal impairment
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A prospective, multi-national, non-interventional study in haemophilia A and B patients with or without inhibitors treated according to routine clinical treatment practice (explorer™6)

A non-interventional study designed to prospectively collect comprehensive data on bleeding episodes and health-related quality of life as well as on physical activity in patients with severe congenital haemophilia A (HA) and B (HB), with or without inhibitors under routine local clinical practice, irrespective of the treatment regimen.
Male
All
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
age ≥ 12 years
Severe (< 1%) congenital hemophilia A or B with or without inhibitors
Pts with inhibitors treated on-demand: ≥ 6 treated (with bypassing agent) bleeding episodes within 24 wks of screening
Pts with severe congenital HA/HB treated on-demand: ≥ 5 treated (with factor product) bleeding episodes within 24 wks of screening
Pts with inhibitors treated with FEIBA prophylaxis: ≥ 2 treated bleeding episodes within 24 wks of screening
Exclusion Criteria:
Known or suspected hypersensitivity to monoclonal antibodies
Previous treatment with concizumabdefined as two or more doses administered.
Planned FVIII/FIX Immune Tolerance Induction (ITI) regimens during the study.
Current or planned treatment with emicizumab.
Any known congenital or acquired coagulation disorder other than congenital hemophilia.
Blood Disorders
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Dose-finding study of SPK-8016 gene therapy in patients with hemophilia A to support future evaluations in individuals with FVIII inhibitors.

SPK-8016-101 is a Phase 1/2a, open-label, non-randomized, dose-finding study designed to evaluate the safety, efficacy, and tolerability of SPK-8016 in adult males with clinically severe hemophilia A and no measurable inhibitor against FVIII.
Cynthia Campbell-Baird, RN at cbaird@pennstatehealth.psu.edu or 717-531-5777
Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03734588
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Clinically severe Hemophilia A
Previous exposure to FVIII therapy
Have >150 exposure days to any recombinant and/or plasma-derived FVIII concentrates
No history of hypersensitivity or anaphylaxis with any FVIII or IV immunoglobulin product
No measurable inhibitor against FVIII
Exclusion Criteria:
Active Hepatitis B or C
Current use of antiviral therapy to treat Hepatitis B or C
Documented significant liver disease
Serological evidence of HIV-1 or HIV-2
Anti-AAV-Spark neutralizing antibody titers >1:5
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

An Open-label, Non-investigational Product, Multi-center, Lead-in Study to Evaluate Prospective Bleeding and Infusion Data of Current FVIII Replacement Therapy in Adult Males with Hemophilia A

SPK-8011-301 is an open-label, non-investigational product lead-in study to collect efficacy and selected safety data on frequency and type of bleeding episodes and FVIII prophylaxis replacement therapy in the usual care setting of adult males with clinically severe hemophilia A (i.e., ≤ 2% IU/dL FVIII activity level), who are negative for neutralizing antibody (Nab) to AAV-Spark200.
Cynthia Campbell-Baird, RN at cbaird@pennstatehealth.psu.edu or 717-531-5777
Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03876301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Clinically severe Hemophilia A
Patients on prophylactic regimen > 2 months
Previous exposure to FVIII therapy
No history of hypersensitivity or anaphylaxis with any FVIII or IV immunoglobulin product
No measurable inhibitor against FVIII
Exclusion Criteria:
Active Hepatitis B or C within past 12 months
Current use of antiviral therapy to treat Hepatitis B or C
Documented significant liver disease
Serological evidence of HIV-1 or HIV-2
Anti-AAV-Spark neutralizing antibody titers >1:1
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors

To establish the effect and investigate safety of daily subcutaneous treatment with concizumab prophylaxis when given to adult and adolescent haemophilia patients without inhibitors.
Male
All
This study is NOT accepting healthy volunteers
NCT04082429
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male aged ≥12 years
Body weight >25 kg at screening
Congenital severe haemophilia A (FVIII < 1%) or moderate/severe B (FIX ≤ 2%)
Documented treatment with coagulation factor containing product in the last 24 weeks
Exclusion Criteria:
Treatment with emicizumab within 180 days before screening
Participation in any clinical trial of an approved or non-approved investigational product within 5 half-lives or 30 days from screening
Known or suspected hypersensitivity to monoclonal antibodies
History of thromboembolic disease
inhibitors ≥0.6 BU in the last 5 years
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

NASH Fitness Intervention for Thrombosis (NASHFit) Trial

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. The most advanced forms of NAFLD are associated with increased liver-related mortality and lower overall survival. The current standard of care for NAFLD is lifestyle changes through diet and exercise. The human genome and regulation of gene expression is influenced by physical activity. NAFLD is a prothrombotic state with derangements in all three phases of hemostasis leading to clinically important clotting events. Exercise can improve coagulation in healthy persons. In this proposal, we seek to begin a line of work to answer the question “Can lifestyle changes effectively mitigate the increased risk of clotting in patients with NAFLD?” focusing initially on the at-risk population genetically susceptible to advanced disease.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03518294
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Nonalcoholic fatty liver disease (NAFLD)
Evidence of hepatic steatosis by imaging
Exclusion Criteria:
>90 minutes/week of at least moderate intensity exercise over the previous three months
Pregnancy
Active cardiac symptoms
Uncontrolled diabetes (changes in medication dosing over the previous three months or hemoglobin A1c >9%)
Blood Disorders, Digestive Systems & Liver Disease, Sports Medicine
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Study of Angelica gigas dietary supplements (Cogni.Q) and potential effects on human immune cells

This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. We had done an earlier study with Korean Angelica supplement and discovered even a single dose of it increased blood neutrophils and NK cells within 24 h. In the new study, Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo) capsules. This is to make sure the immune boosting actions are really from the Korean Angelica supplement. Approximately 40 men will take part in this research study at Hershey Medical Center.
Male
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male subjects 21 to 65 years of age
Subjects weighing between 110 to 240 pounds; their body mass index (BMI) should be in the range of 19=< BMI >=30
Subjects having normal hepatic, renal function as assessed by history, physical and clinical chemistry analysis (CMP eGFR).
Subjects with normal blood pressure (systolic below 120 mm Hg and diastolic below 80 mm Hg)
Exclusion Criteria:
Subjects positive for HIV, HBV and HCV (self-reported)
Subjects taking any kind of prescription medications regularly or within 10 days of the study will be excluded.
Subjects taking dietary or herbal supplements that contain AGN (e.g. Cogni.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) within 10 days of the study.
Non-English-speaking subjects
Infectious Diseases & Immune System, Blood Disorders, Food & Nutrition
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

An open-label, multinational study of fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B.

A study to confirm the appropriate dose of fitusiran when given to severe Hemophilia A or B patients with inhibitors between the ages of 1 and &lt;12 years old.
Male
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT03974113
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Severe hemophilia A or B (FVIII <1% or FIX ≤2%)
Inhibitory antibodies to FVIII or FIX
Age 1 to <12 years
Exclusion Criteria:
AT activity <60% at screening
Co-existing thrombophilic disorder
Central or peripheral indwelling catheter, with a hx of venous access complications
Anticipated need of surgery during the study
Presence of clinically significant liver disease
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in von Willebrand Disease for Childbirth

Specific guidance is lacking for pregnant women with von Willebrand Disease (VWD) and delivery planning in terms of how high a von Willebrand factor (VWF) level should be achieved. Specifically, guidance is lacking on whether replacement therapy drugs (Wilate &amp; Tranexamic Acid) should target a VWF minimum level. This study is a prospective study to document the rate of primary postpartum hemorrhage (PPH) and the effectiveness of the dosing of Wilate, looking to provide increased management and guideline recommendations.
Cynthia Campbell-Baird at cbaird@pennstatehealth.psu.edu or 717-531-5777
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04146376
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
VWD patients defined prepartum as Type 1 per National Heart, Lung & Blood Institute
Written informed constent from the patient prepartum
VWF & FVIII patient levels in gestational week 34-38 will determine enrollment group
Exclusion Criteria:
Age<18 years
Presence of liver disease or renal disears , clinical suspicion of or diagnosis of pre-eclampsia/eclampsia, HELLP syndrome, TTP, DIC, etc.
Presence of other concurrent disorder of hemostasis, platelet dysfunction or collagen disorders
Blood Disorders
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA